| 尼妥珠单抗联合IMRT治疗老年局部晚期食管癌患者的疗效观察 |
| |
| 引用本文： | 李路路,陈 剑,张鼎儒,郭宇飞.尼妥珠单抗联合IMRT治疗老年局部晚期食管癌患者的疗效观察[J].现代肿瘤医学,2020,0(8):1298-1300. |
| |
| 作者姓名： | 李路路 陈 剑 张鼎儒 郭宇飞 |
| |
| 作者单位： | 1.深圳市盐田区人民医院肿瘤科，广东 深圳 518081；2.焦作市第二人民医院放疗科，河南 焦作 454001 |
| |
| 摘 要： | 目的:探讨尼妥珠单抗联合适型调强放射治疗（IMRT）在局部晚期老年食管癌患者中的疗效和安全性。方法:67例老年局部晚期食管癌患者随机分为试验组和对照组，试验组34例予尼妥珠单抗联合IMRT治疗，对照组33例只行IMRT治疗。结果:试验组与对照组的近期有效率（RR）分别为85.2%和63.6%，疾病控制率（DCR）分别为97.1%和81.8%，差异均有统计学意义(P＜0.05）；1、2、3年生存率虽然试验组较对照组有提高，但差异无统计学意义(P＞0.05）；2组不良反应相似，差异无统计学意义(P＞0.05）。结论:尼妥珠单抗联合IMRT可以明显提高局部晚期老年食管癌患者的RR和DCR，但未明显提高患者的1、2、3年生存率。
|
| 关 键 词： | 尼妥珠单抗 局部晚食管癌 老年患者 适型调强放射治疗 |
The efficacy and safety of nimotuzumab combined with IMRT in locally advanced esophageal carcinoma of elderly patients |
| |
| Li Lulu,Chen Jian,Zhang Dingru,Guo Yufei.The efficacy and safety of nimotuzumab combined with IMRT in locally advanced esophageal carcinoma of elderly patients[J].Journal of Modern Oncology,2020,0(8):1298-1300. |
| |
| Authors: | Li Lulu Chen Jian Zhang Dingru Guo Yufei |
| |
| Affiliation: | 1.Department of Oncology，the People's Hospital of Yantian District in Shenzhen，Guangdong Shenzhen 518081，China；2.Department of Rediation Oncology,the Second People's Hospital of Jiaozuo,Henan Jiaozuo 454001,China. |
| |
| Abstract: | Objective:To evaluate the efficacy and safety of nimotuzumab combined with concurrent intensity-modulated radiotherapy(IMRT) for elderly patients with locally advanced esophageal carcinoma.Methods:Sixty-seven elderly patients with esophageal carcinoma randomly divided into the experimental group(34 patients) and the control group(33 patients).Thirty-four patients of the trial group received nimotuzumab combined with IMRT.Thirty-three patients of the control group received only IMRT.Results:The resent response rate(RR) of the experimental group and control group were 85.2% and 63.6%,and the disease control rate(DCR) were 97.1% and 81.8%,respectively(P＜0.05).The 1-,2-,3-survival rate of the experimental group were improved to some degree,but the result don' t have difference(P＞0.05).The adverse effects of the two group had similarity(P＞0.05).Conclusion:Nimotuzumab combined with IMRT could increase RR and DCR in the elderly patients with locally advance esophageal carcinoma,but it couldn't significantly improve the 1-,2-,3-survival rate. |
| |
| Keywords: | nimotuzumab locally advanced esophageal carcinoma elderly patients intensity-modulated radiotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
